at Investor's Business Daily (Mon, 6:42PM)
Mylan (MYL) may be looking for acquisitions to build upon its product line and expand geographically, and is said to be considering deals valued at “well over” $4B. Key areas it's looking to bolster include specialty drugs and deals to widen its range of delivery, including firms that produce topically applied drugs, which would compliment its already strong core pill-related business. Some targets its considering globally include generic manufacturers in emerging markets, such as Jordanian drug maker Hikma Pharmaceuticals.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 21, 2015)
at Zacks.com (Jan 12, 2015)
at Zacks.com (Jan 9, 2015)
at Zacks.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs